Presented at ACC as a Late-Breaking Clinical Trial, VALOR-HCM explores Mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive hypertrophic cardiomyopathy. Dr. Steven Nissen and Dr. Milind Desai, principal investigator, discuss the purpose, patient selection, and findings of the VALOR-HCM trial.
Learn more about Dr. Steven Nissen https://my.clevelandclinic.org/staff/1185-steven-nissen#biography
Learn more about Dr. Milind Desai https://my.clevelandclinic.org/staff/6670-milind-desai#biography
See the ConsultQD article here
https://consultqd.clevelandclinic.org/mavacamten-significantly-reduces-patients-need-for-septal-reduction-therapy-over-16-weeks/
See the Cleveland Clinic News Release here
https://newsroom.clevelandclinic.org/2022/04/02/cleveland-clinic-led-trial-shows-drug-effective-in-nearly-80-of-patients-with-hypertrophic-cardiomyopathy/